These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 26746091)
1. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091 [TBL] [Abstract][Full Text] [Related]
2. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Kahler-Ribeiro-Fontana S; Pagan E; Magnoni F; Vicini E; Morigi C; Corso G; Intra M; Canegallo F; Ratini S; Leonardi MC; La Rocca E; Bagnardi V; Montagna E; Colleoni M; Viale G; Bottiglieri L; Grana CM; Biasuz JV; Veronesi P; Galimberti V Eur J Surg Oncol; 2021 Apr; 47(4):804-812. PubMed ID: 33092968 [TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer. Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218 [TBL] [Abstract][Full Text] [Related]
4. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032 [TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: Work in progress. Rubio IT Eur J Surg Oncol; 2016 Mar; 42(3):326-32. PubMed ID: 26774943 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382 [TBL] [Abstract][Full Text] [Related]
7. "Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients". van Wely BJ; van den Wildenberg FJ; Gobardhan P; van Dalen T; Borel Rinkes IH; Theunissen EB; Wijsman JH; Ernst M; van der Pol CC; Madsen EV; Vles WJ; Wauters CA; de Wilt JH; Strobbe LJ Eur J Surg Oncol; 2012 Oct; 38(10):925-31. PubMed ID: 22633152 [TBL] [Abstract][Full Text] [Related]
8. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy. Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734 [TBL] [Abstract][Full Text] [Related]
9. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362 [TBL] [Abstract][Full Text] [Related]
10. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361 [TBL] [Abstract][Full Text] [Related]
11. Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up. Ogawa Y; Ikeda K; Watanabe C; Kamei Y; Tokunaga S; Tsuboguchi Y; Inoue T; Fukushima H; Ichiki M Surg Today; 2018 Jan; 48(1):87-94. PubMed ID: 28647776 [TBL] [Abstract][Full Text] [Related]
12. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Yegiyants S; Romero LM; Haigh PI; DiFronzo LA Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977 [TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK; JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169 [TBL] [Abstract][Full Text] [Related]
14. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients. Martelli G; Boracchi P; Orenti A; Lozza L; Maugeri I; Vetrella G; Agresti R Eur J Surg Oncol; 2014 Jul; 40(7):805-12. PubMed ID: 24768443 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. Galimberti V; Manika A; Maisonneuve P; Corso G; Salazar Moltrasio L; Intra M; Gentilini O; Veronesi P; Pagani G; Rossi E; Bottiglieri L; Viale G; Rotmensz N; De Cicco C; Grana CM; Sangalli C; Luini A Eur J Surg Oncol; 2014 Oct; 40(10):1203-8. PubMed ID: 25186914 [TBL] [Abstract][Full Text] [Related]
16. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. Martelli G; Miceli R; Folli S; Guzzetti E; Chifu C; Maugeri I; Ferranti C; Bianchi G; Capri G; Carcangiu ML; Paolini B; Agresti R; Ferraris C; Piromalli D; Greco M Eur J Surg Oncol; 2017 Nov; 43(11):2012-2020. PubMed ID: 28912071 [TBL] [Abstract][Full Text] [Related]
17. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362 [TBL] [Abstract][Full Text] [Related]
18. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes. Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919 [TBL] [Abstract][Full Text] [Related]
19. Positive axillary sentinel lymph node: is axillary dissection always necessary? Galimberti V; Chifu C; Rodriguez Perez S; Veronesi P; Intra M; Botteri E; Mastropasqua M; Colleoni M; Luini A; Veronesi U Breast; 2011 Oct; 20 Suppl 3():S96-8. PubMed ID: 22015302 [TBL] [Abstract][Full Text] [Related]
20. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Jones JL; Zabicki K; Christian RL; Gadd MA; Hughes KS; Lesnikoski BA; Rhei E; Specht MC; Dominguez FJ; Smith BL Am J Surg; 2005 Oct; 190(4):517-20. PubMed ID: 16164912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]